Charles River Labs CEO Executes 10b‑5 Buy‑Sell‑Back Plan, Netting $100/share Gain in One Day

Insider Activity Spotlight: Charles River Laboratories on the Radar

Recent trading data from the 2026‑10‑05 filing shows that Parisotto Shannon M, the Chief Executive and Vice President of Discovery & Safety Assessment, executed a Rule 10b‑5 trading plan purchase of 981 shares at $208.44, followed by a sale of the same number at $308.44 the same day. The dual transaction, executed under a pre‑arranged plan, is typical of a “buy‑sell‑back” strategy that allows insiders to lock in gains while maintaining regulatory compliance. The fact that the purchase price was below the closing price of $304.96, coupled with the 1.79 % weekly upside, signals that Parisotto was positioned to capture a modest upside in the short term without exposing the company to significant risk.

What Does This Mean for Investors?

The pattern of Parisotto’s recent trades—multiple buys and sells between late May and early October—shows a balanced approach: he occasionally takes profits when the stock rallies, then reinvests when valuation dips. For the market, this can be a sign of confidence: insiders are willing to invest when they see value, yet they’re not over‑exposed. The 52‑week high of $333.30 and a robust annual gain of 74 % suggest that the company’s revenue growth and digital lab initiatives are resonating with the market. However, the negative price‑earnings ratio (-63.07) indicates that earnings are still negative, so investors should focus on the company’s long‑term pipeline rather than short‑term earnings spikes.

Parisotto Shannon M: A Transaction Profile

Parisotto’s insider activity over the past five months reveals a consistent pattern: he buys when the stock is under $250, sells around $280‑$310, and sometimes sells a large block in a single trade (e.g., 4,361 shares on 2026‑05‑29). He also frequently exercises options (right to buy) and then sells the acquired shares, a classic “option‑to‑sell” strategy that allows him to lock in gains while retaining ownership. This disciplined approach signals that Parisotto is comfortable with the company’s trajectory but remains vigilant about market volatility. His trading volume relative to the company’s 10‑year average suggests that he is an active participant, yet his trades are modest relative to his overall holdings (the current holding of 9,680 shares is less than 1 % of the total shares outstanding).

Company‑Wide Insider Activity

The broader insider landscape is dominated by a few senior executives, notably EVP CFO Coleman Glenn and EVP VP of Corporate Strategy LaPlume. Both have made sizeable purchases in August, aligning with a broader trend of management buying into the company as it scales its digital platform offering. The sale by CEO Birgit Girshick on 2026‑08‑19 indicates a strategic divestment, perhaps to rebalance her personal portfolio. These moves, combined with Parisotto’s consistent trading pattern, paint a picture of a management team that is generally bullish but cautious about concentration risk.

Strategic Outlook for Investors

Charles River’s recent partnership with Autolomous to launch the Apollo Orchestrate platform positions it at the forefront of automated pre‑clinical testing. This move, coupled with steady investor confidence shown through insider buys, suggests a strong near‑term growth engine. Investors should watch for upcoming earnings releases and any further large‑block trades that could signal a shift in sentiment. In short, insiders are buying and selling strategically, reinforcing a narrative of confidence tempered by prudent risk management.